Skip to Main Content
Phase II

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma

  • Study HIC#:2000027272
  • Last Updated:06/12/2023

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing on CPI treatment, CPI-naïve HCC, and treatment-naïve Endometrial.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Christina Wiess

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact, or call +18779788343 for more information.

    Trial Purpose and Description

    Patients with melanoma will be enrolled into two parallel cohorts; in one cohort (Intravenous melanoma cohort) patients will receive IV VV1 and patients in the other cohort (Intratumoral melanoma cohort) will receive both IV VV1 and Intratumoral VV1; both cohorts will receive IV cemiplimab in combination therapy with VV1 treatment. Patients with NSCLC, HCC or endometrial cancer will receive IV VV1 and IV cemiplimab combination therapy.

    Eligibility Criteria

    Key Inclusion Criteria

    1. Age ≥18 years on day of signing informed consent.
    2. Specific by tumor cohorts:
      • For the HCC cohort, confirmed diagnosis of inoperable HCC by histology or clinical/radiological criteria. i. No prior therapy with a PD-(L)1 immune checkpoint inhibitor (CPI) (prior sorafenib is permitted). ii. No or one prior line of systemic therapy only. iii. Child Pugh Score A or B7.
      • For the NSCLC cohort, histologically confirmed diagnosis of advanced and/or metastatic NSCLC in which radiological progression has been demonstrated during therapy with a PD(L)1 immune CPI and for which no existing options are felt to provide clinical benefit (only one line of PD-(L)1 therapy is permitted).

      Progression during or following 1 or more prior regimen(s) and no more than 3 prior therapeutic regimens for metastatic disease.

      • For the melanoma cohorts, histologically confirmed diagnosis of advanced and/or metastatic melanoma in which radiological progression has been demonstrated during therapy with a PD(L)1 immune CPI and for which no existing options are considered to provide clinical benefit (only one line of PD(L)1 therapy is permitted). Progression on ipilimumab is not required. Note: For IT melanoma cohort:
        • i. At least one tumor lesion amenable to repeated IT injection via palpation or ultrasound. Injection of deep visceral lesions is not permitted.
        • ii. Agrees to provide a newly obtained biopsy of injected and witness lesions prior to start of study treatment, and to repeat biopsies twice during study treatment, and to providing the acquired tissue for biomarker analysis. Tissue obtained for the biopsy must not be previously irradiated, but a new or progressing lesion in the radiation field is acceptable.
      • For the endometrial cancer cohort, histologically confirmed diagnosis of advanced and/or metastatic endometrioid endometrial adenocarcinoma. Eligible patients will not have had any prior systemic therapy in the metastatic setting.
    3. For patients treated with prior anti-PD-(L)1 therapy:
      • Last dose of anti-PD-(L)1 must be within 12 weeks of initiating study treatment.
      • Patient must have received at least 4 doses on q2w, 3 doses on q3w or 2 doses on q4w schedule of the previous anti-PD-(L)1 therapy.
      • Progression on prior anti-PD-(L)1 therapy must be defined by:
      • Documented radiographic progression on a single radiographic scan, if treatment with anti-PD-(L)1 was ≥ 16 weeks.
      • Documented radiographic progression on two consecutive radiographic scans at least 4 weeks apart, if treatment with anti-PD-(L)1 therapy was between 8 - 16 weeks; if radiographic progression is accompanied with clinical progression, then a single scan assessment may be used.
      • If progression was only in lymph nodes, biopsy to provide histological confirmation of progression in the lymph node is required.
    4. Measurable disease based on RECIST 1.1.

    Key Exclusion criteria: Patients meeting any of the following exclusion criteria at screening/Day -1 of first dosing will not be enrolled in the study

    1. Availability of and patient acceptance of an alternative curative therapeutic option.
    2. Recent or ongoing serious infection, including any active Grade 3 or higher per the National Institute of Cancer Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE, v5.0) viral, bacterial, or fungal infection within 2 weeks of registration.
    3. Known seropositivity for and with active infection by the human immunodeficiency virus (HIV).

      • Patients who are seropositive for HIV but are receiving antiviral therapy and show non-detectable viral load and a normal CD4 T cell count for at least 6 months are eligible.

    4. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV). Patients who are hepatitis B surface antigen (HBsAg) negative and HBV viral DNA negative are eligible.
      • Patients who had HBV but have received an antiviral treatment and show non-detectable viral DNA for 6 months are eligible.
      • Patients who are seropositive because of HBV vaccine are eligible.
    5. Seropositive for and with active viral infection with hepatitis C virus (HCV).

      • Patients who had HCV but have received an antiviral treatment and show no detectable HCV viral DNA for 6 months are eligible.

    6. Known history of active or latent TB (bacillus tuberculosis).
    7. Any concomitant serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months).
    8. Prior therapy within the following timeframe before the planned start of study treatment as follows:
      • Small molecule inhibitors, and/or other investigational agent: ≤ 2 weeks or 5 half-lives, whichever is shorter.
      • Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
      • Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.
    9. New York Heart Association (NYHA) classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia).
    10. Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.
    11. Immunodeficiency or immunosuppression
    12. History of Grade 3 or 4 immune-mediated adverse reaction to immune CPIs.
    13. Toxicities from previous therapies that have not resolved to a Grade 1 or less.
    14. History of non-infectious pneumonitis that required steroids, or current pneumonitis.